249,265 Shares in ImmunityBio, Inc. $IBRX Purchased by MOR Wealth Management LLC

MOR Wealth Management LLC bought a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 249,265 shares of the company’s stock, valued at approximately $494,000.

Other institutional investors also recently bought and sold shares of the company. Armistice Capital LLC acquired a new stake in shares of ImmunityBio during the second quarter worth about $20,497,000. Heights Capital Management Inc. acquired a new stake in ImmunityBio during the 3rd quarter worth approximately $16,152,000. Vanguard Group Inc. boosted its position in ImmunityBio by 26.8% in the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after buying an additional 5,837,898 shares during the period. Woodline Partners LP grew its stake in shares of ImmunityBio by 53.7% in the third quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock worth $13,032,000 after acquiring an additional 1,851,854 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in shares of ImmunityBio by 224.9% during the third quarter. Two Sigma Investments LP now owns 2,607,860 shares of the company’s stock worth $6,415,000 after acquiring an additional 1,805,297 shares during the period. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $7.38 on Monday. The business has a 50-day moving average of $7.68 and a two-hundred day moving average of $4.25. The company has a market capitalization of $7.59 billion, a price-to-earnings ratio of -19.42 and a beta of -0.04. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. As a group, equities research analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold 501,967 shares of company stock worth $4,466,412 over the last quarter. 69.48% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on IBRX shares. D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a research note on Monday, March 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Jefferies Financial Group lifted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Piper Sandler restated an “overweight” rating and set a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.40.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Independent Data Monitoring Committee says the pivotal randomized BCG‑naïve NMIBC trial is adequately powered and ImmunityBio’s supplemental BLA submission remains on track for 2026 — supports ANKTIVA’s regulatory path. Business Wire: Trial power check & BLA on track
• Positive Sentiment: Regulatory win: ANKTIVA approved in Macau SAR — expands commercial footprint for the lead biologic. MSN: ANKTIVA approval in Macau
• Positive Sentiment: Analyst action: a reported price‑target increase (to $15.10) signals some sell‑side confidence in upside potential. MSN: Price target raised
• Neutral Sentiment: Industry comparison pieces highlight that IBRX’s upside is tied to single‑drug success (ANKTIVA) versus larger peers’ broader pipelines — useful context for risk/reward but not immediate news. Zacks: IBRX vs. Moderna analysis
• Neutral Sentiment: Market note: some premarket commentary reflected the clinical update but also showed intraday volatility — indicates investors are parsing both upside and headline risk. Benzinga: Trial clears power check (and market reaction)
• Negative Sentiment: Major near‑term negative: a flurry of securities‑fraud class actions and investigations were filed/announced by multiple law firms (Rosen, Faruqi & Faruqi, Robbins, Pomerantz, Block & Leviton, Portnoy, Kaplan Fox, etc.) related to activity between Jan 19–Mar 24, 2026; investors face potential litigation costs, distraction, and reputational risk — lead‑plaintiff motions are due (May 26, 2026). PR Newswire: Rosen files class action
• Negative Sentiment: Regulatory/legal pressure amplified by reports of an FDA warning that has put ANKTIVA expectations and valuation in focus — raises execution and approval risk. Yahoo Finance: FDA warning on ANKTIVA

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.